Amyotrophic Lateral Sclerosis (ALS)

Research

Amyotrophic Lateral Sclerosis - Research

Intense research is being conducted in many areas related to ALS, from basic science seeking the roots of the disease, to therapy development to find effective treatments.

Since inception, MDA has dedicated over $344 million to ALS research and health care services. In the past five years alone, MDA has spent over $46 million toward ALS research.

Causes/Inheritance

Amyotrophic Lateral Sclerosis - Causes/Inheritance

About 5 to 10 percent of ALS is familial — meaning it arises in families in which there is a history of ALS. Several genes associated with ALS have been identified or at least mapped to a specific region of a chromosome.

Diagnosis

Amyotrophic Lateral Sclerosis - Diagnosis

There are some specific criteria for the diagnosis of ALS known as the El Escorial criteria. (They're named after a conference center in Spain, where they were developed in 1990.)

Amyotrophic Lateral Sclerosis

Description: 

Unite with MDA, Stop ALS and Save Lives

#EveryAugustUntilACure

ALS Research Briefs

Patients Like Me online lithium study utilized social media

An observational study of data self-reported on the online forum Patients Like Me by people with ALS who elected to take the drug lithium carbonate has shown two things:

ISIS-SOD1-Rx: So Far, So Good

Early results of a phase 1 clinical trial of ISIS-SOD1-Rx, an antisense oligonucleotide drug for SOD1-related amyotrophic lateral sclerosis (ALS), show the drug appears to be safe and well tolerated at the lowest dosage level, based on a group of six patients who received 12-hour infusions of it into their spinal fluid.

ALS TDI Webinar Discusses Current Research

The state of the science in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease), current lines of research, efforts to establish a TDP43 research mouse colony, and a primer on protein-based therapies were the topics of a webcast on April 7, 2011, presented by ALS Therapy Development Institute (ALS TDI) CEO and Chief Scientific Officer Steve Perrin, and colleagues.

ALS Research Briefs from 2011 AAN Meeting

Neuralstem's trial of spinal cord injections of stem cells is on track

MDA Surveying Families about ‘Cost of Illness’

Most people affected by neuromuscular disease know all too well that their condition is costly. MDA wants to find out just how costly — and then translate those figures into terms that will speak to policy makers.

Scholarships, Grants Available to People with Disabilities

(Update 9/14/11: The 2011 scholarship winners have been selected. To view a list of winners visit www.deshae.org/cmms/awards/2011/scholars.pdf. Applications for quality of life grants continue to be accepted and are awarded on an ongoing basis.)

Pages